Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

mdxhealth

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%
2023 gross margin expanded by 10.7 percentage points over prior year
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Michael K. McGarrity, CEO of mdxhealth, commented: “Our fourth quarter and full year 2023 results reflect our continued commitment to commercial execution and operational discipline that has driven significant gross margin expansion across our business. With each passing quarter, we continue to build on our position as a leading precision diagnostics company rooted in our industry-leading technology, focus on the highest quality customer experience, and our unwavering commitment towards improving patient outcomes. We remain well positioned to build upon this success as we actively evaluate multiple, high-growth opportunities that could further strengthen and complement our existing menu. In 2024, we expect to deliver continued topline growth and operating execution that will lead to adjusted EBITDA profitability in the first half of 2025.”

Key Highlights:

• Completed transition to sole listing of its shares on NASDAQ

• Secured Medicare coverage for the Company’s Select mdx test

• Fourth quarter revenue of $19.4 million, an increase of 50% over prior year period

• 2023 revenue of $70.2 million, an increase of 89% or 42% excluding GPS

Financial review for the fourth quarter and year ended December 31, 2023

USD in ‘000 (except per share data) Unaudited		Three months ended December 31				Twelve months ended December 31
		2023	2022	% Change		2023	2022	% Change
Revenue		19,398	12,891	50%		70,193	37,054	89%
Cost of goods		(6,727)	(5,667)	19%		(26,264)	(17,835)	47%
Gross Profit		12,671	7,224	75%		43,929	19,219	129%
Operating expenses		(18,977)	(16,171)	17%		(71,256)	(57,119)	25%
Operating loss		(6,306)	(8,947)	(30%)		(27,327)	(37,900)	(28%)
Net loss		(10,720)	(12,438)	(14%)		(43,100)	(44,044)	(2%)
Basic and diluted loss per share		(0.39)	(0.76)	(48%)		(1.66)	(2.78)	(40%)

Fourth Quarter 2023 Financial Results

Revenue increased 50% to $19.4 million compared to $12.9 million for the prior year. Revenue was comprised of $8.8 million from GPS, $5.9 million from Confirm mdx, $3.2 million from Resolve mdx, and $1.3 million from Select mdx.

Gross margins were 65.3% compared to 56.0% for the prior year, an improvement of 9.3 percentage points attributed to contribution from Select mdx reimbursement, coupled with cost management and expanded coverage across our menu.

Operating expenses increased 17% to $19.0 million compared to $16.2 million for the prior year, driven by increases in R&D expense, increased sales and marketing activity from the GPS acquisition, as well as $1.7 million of non-recurring expenses, primarily attributed to the transition to a sole listing on NASDAQ.

Net loss decreased 14% to $10.7 million compared to $12.4 million for the prior year, driven by the factors mentioned above, partially offset by an increase of $2.1 million in financial expenses, of which $1.8 million was non-cash.

Full Year 2023 Financial Results

Revenue increased 89% to $70.2 million compared to $37.1 million for the prior year. Excluding GPS, revenue increased 42% to $39.3 million compared to $27.7 million for the prior year. Revenue was comprised of $30.9 million from GPS, $24.8 million from Confirm mdx, $9.7 million from Resolve mdx, and $4.5 million from Select mdx.

Gross margins were 62.6% compared to 51.9% for the prior year, an improvement of 10.7 percentage points attributed to contribution from Select mdx reimbursement, cost management, expanded coverage across our menu, and a higher contribution from GPS to total revenue.

Operating expenses increased 25% to $71.3 million compared to $57.1 million for the prior year, primarily driven by the acquisition of the GPS test in August 2022, and includes $2.6 million of non-recurring expenses, primarily attributed to the transition to a sole listing on NASDAQ.

Net loss decreased 2% to $43.1 million compared to $44.0 million for the prior year, driven by the factors mentioned above, partially offset by an increase of $11.4 million in financial expenses, of which $9.1 million was non-cash and primarily related to the GPS contingent consideration.

Cash and cash equivalents as of December 31, 2023, were $22.4 million.

Business Update and Outlook for 2024

The Company is maintaining its previously issued 2024 revenue guidance of $79-81 million and confirms its view of expected adjusted EBITDA profitability in the first half of 2025.

Conference Call

Michael K. McGarrity, Chief Executive Officer and Ron Kalfus, Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The call will be conducted in English and a replay will be available for 30 days.

To participate in the conference call, please select your phone number below:

United States: 1-888-886-7786

Belgium: 0800 76018

The Netherlands: 0800 022 7908

United Kingdom: 1-800-652-2435

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1655339&tp_key=a93e4440eb

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled
start time.

About mdxhealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

info@mdxhealth.com

LifeSci Advisors (IR & PR)
US: +1 949 271 9223

ir@mdxhealth.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; expectations for development of new or improved products and services and their impact on patients; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

Non-IFRS Measures. The Company’s reference to adjusted EBITDA is a forward-looking statement about the Company’s future financial performance, and is a non-IFRS measure that excludes a number of expense items that are included in net loss, including adjustments for items like stock-based compensation, acquisition and integration costs, impairment of long-lived assets, fair-value adjustment, loan extinguishment costs, as well as other non-operating, non-recurring expenses that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. Non-IFRS financial information has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS, and such information is referenced for supplemental information purposes only. Management does not forecast many of the excluded items for internal use, as these are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort, and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS measures could significantly impact the Company's IFRS results.

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.

MDxHealth SA and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

		Three Months Ended December 31,								Year Ended December 31,
In thousands of $ (except per share amounts)		2023				2022				2023				2022
Revenues		$	19,398			$	12,891			$	70,193			$	37,054
Cost of goods & services sold			(6,727	)			(5,667	)			(26,264	)			(17,835	)
Gross profit			12,671				7,224				43,929				19,219
Research and development expenses			(1,829	)			(799	)			(6,376	)			(5,497	)
Selling and marketing expenses			(9,484	)			(8,467	)			(36,915	)			(25,704	)
General and administrative expenses			(6,730	)			(5,746	)			(23,010	)			(23,308	)
Amortization of intangible assets			(1,127	)			(1,559	)			(4,494	)			(3,169	)
Other operating (expense) income, net			193				400				(461	)			559
Operating loss			(6,306	)			(8,947	)			(27,327	)			(37,900	)
Financial expenses, net			(4,413	)			(3,363	)			(15,772	)			(6,144	)
Loss before income tax			(10,719	)			(12,310	)			(43,099	)			(44,044	)
Income tax			(1	)			(128	)			(1	)			0
Loss for the period		$	(10,720	)		$	(12,438	)		$	(43,100	)		$	(44,044	)
Loss per share attributable to parent
Basic and diluted		$	(0.39	)		$	(0.76	)		$	(1.66	)		$	(2.78	)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

In thousands of $				December 31, 2023				December 31, 2022
ASSETS
Non-current assets
Goodwill				$	35,926			$	35,926
Intangible assets					44,337				46,166
Property, plant and equipment					4,956				3,791
Right-of-use assets					4,989				4,103
Financial assets					763				-
Total non-current assets					90,971				89,986
Current assets
Inventories					2,779				2,327
Trade receivables					11,088				9,357
Prepaid expenses and other current assets					1,914				1,962
Cash and cash equivalents					22,380				15,503
Total current assets					38,161				29,149
TOTAL ASSETS				$	129,132			$	119,135
EQUITY
Share capital				$	173,931			$	133,454
Issuance premium					153,177				153,177
Accumulated deficit					(331,446	)			(288,346	)
Share-based compensation					12,139				11,474
Translation reserve					(593	)			(444	)
Total equity					7,208				9,315
LIABILITIES
Non-current liabilities
Loans and borrowings					35,564				34,914
Lease liabilities					3,578				3,091
Other non-current financial liabilities					63,259				53,537
Total non-current liabilities					102,401				91,542
Current liabilities
Loans and borrowings					643				616
Lease liabilities					1,480				1,172
Trade payables					8,811				10,178
Other current liabilities					5,694				3,985
Other current financial liabilities					2,895				2,327
Total current liabilities					19,523				18,278
Total liabilities					121,924				109,820
TOTAL EQUITY AND LIABILITIES				$	129,132			$	119,135

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

				Year Ended December 31,
In thousands of $ For the years ended December 31				2023					2022
CASH FLOWS FROM OPERATING ACTIVITIES
Operating loss				$	(27,327	)		$	(37,900	)
Depreciation and amortization					6,859				4,909
Impairment					-				44
Share-based compensation					665				867
Other non-cash transactions					421				(473	)
Cash used in operations before working capital changes					(19,382	)			(32,553	)
Increase (-) in inventories					(452	)			(416	)
Increase (-) in receivables					(1,683	)			(5,122	)
Increase (+) in payables					20				3,973
Net cash outflow from operating activities					(21,497	)			(34,118	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment					(2,747	)			(2,789	)
Acquisition and generation of intangible assets					(2,272	)			(1,374	)
Acquisition of Genomic Prostate Score Business					-				(25,000	)
Interests received					1,088				125
Net cash outflow from investing activities					(3,931	)			(29,038	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of shares, net of transaction costs					39,599				-
Proceeds from loan obligation					-				34,291
Repayment of loan obligation and debt extinguishment costs					(1,659	)			(10,805	)
Amendment fee related to GPS asset purchase agreement					(250	)			-
Payment of lease liability					(1,610	)			(1,358	)
Payment of interest					(3,610	)			(1,412	)
Other financial expenses					(190	)			-
Net cash inflow from financing activities					32,280				20,716
Net increase (+) / decrease (-) in cash and cash equivalents					6,852				(42,440	)
Cash and cash equivalents at beginning of the financial year					15,503				58,498
Effect on exchange rate changes					25				(555	)
Cash and cash equivalents at end of the financial year				$	22,380			$	15,503

Attachment

• MDXH FY 2023